- Home
- MYGN
MYGN
Myriad Genetics Inc.
as 12-18-2024 11:40am EST
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 2.0B | IPO Year: | 1995 |
| Target Price: | $23.92 | AVG Volume (30 days): | 904.0K |
| Analyst Decision: | Hold | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.30 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.81 - $29.30 | Next Earning Date: | 11-07-2024 |
| Revenue: | $823,600,000 | Revenue Growth: | 12.15% |
| Revenue Growth (this year): | 13.82% | Revenue Growth (next year): | 4.59% |
Stock Insider Trading Activity of Myriad Genetics Inc. (MYGN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| DIAZ PAUL J | MYGN | President and CEO | Oct 11 '24 | Sell | $22.93 | 15,000 | $343,950.00 | 962,378 |
Latest Myriad Genetics Inc. News
MYGN Breaking Stock News: Dive into MYGN Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?
MT Newswires
7 days ago
Myriad Genetics Expects to Reach Resolution With UnitedHealthcare Over Pharmacogenetic Testing Before Yearend
Argus Research
8 days ago
MYGN: Lowering target price to $12.00
GlobeNewswire
8 days ago
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
GlobeNewswire
8 days ago
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
GlobeNewswire
8 days ago
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
Zacks
8 days ago
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain?
GlobeNewswire
9 days ago
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
Compare MYGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MYGN Myriad Genetics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.